NCT06136884 - A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2023

Primary Completion Date

January 28, 2027

Study Completion Date

January 27, 2028

Conditions

Solid Tumor MalignanciesBrain Metastases From Solid Tumors

Interventions

DRUG

AO-252

AO-252 will be administered oral tablets or capsules daily

Trial Locations (5)

RECRUITING

Next Oncology -Virginia, Fairfax

RECRUITING

Karmanos Cancer Institute, Detroit

RECRUITING

Oklahoma Univeristy, Oklahoma City

RECRUITING

Mary Crowley Cancer Research, Dallas

RECRUITING

The University of Texas M.D. Anderson Cancer Center, Houston